Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
Recruiting · NCT05174351 · Interventional (participants receive a specific treatment) · Lead sponsor: UConn Health
View the official record on ClinicalTrials.gov →Interventions studied
beta blocker discontinuation
What this trial is about
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
Who can take part
Age range
50 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100
- N=30 (Target: 30).
- Age: 50 \~ 80 years.
- ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.
- Chronic loop diuretic use
- Currently on beta-blocker
Exclusion criteria
- Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.
- Heart rate \> 100 bpm
- Recent hospitalization due to HF within 3 months
- Non-English speaker
Where it is running
1 location listed across 1 US state.
- UConn Health / John Dempsey Hospital - Farmington, Connecticut, United States